Summary:
[unable to retrieve full-text content]CoinspeakerJohnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly The pharmaceutical segment reported the highest sales with about .71 billion, followed by MedTech with a total sales of about .78 billion, and the remaining accrued from the consumer health segment. Johnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly
Topics:
Steve Muchoki considers the following as important: Business News, jnj, jnj stock, johnson & johnson stock, Market News, News, Stocks, Wall Street
This could be interesting, too:
[unable to retrieve full-text content][unable to retrieve full-text content]CoinspeakerJohnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly The pharmaceutical segment reported the highest sales with about .71 billion, followed by MedTech with a total sales of about .78 billion, and the remaining accrued from the consumer health segment. Johnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly
Topics:
Steve Muchoki considers the following as important: Business News, jnj, jnj stock, johnson & johnson stock, Market News, News, Stocks, Wall Street
This could be interesting, too:
Emily John writes SEC Ends Yuga Labs Probe with No Charges
Emily John writes Over 1200 Crypto ATMs Shutdown in US Amid Crash
Bilal Hassan writes Morocco Cracks Down on Crypto Property Deals
Emily John writes Football Legend Ronaldinho Joins Crypto With STAR10 Token
Coinspeaker
Johnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly
The pharmaceutical segment reported the highest sales with about $13.71 billion, followed by MedTech with a total sales of about $7.78 billion, and the remaining accrued from the consumer health segment.
Johnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly